The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 19)
Therapeutic Pipeline Program, 2014
Cognitive impairments — common in Parkinson's disease — are associated with an imbalance in neurotransmitters (substances that allow nerve cells to communicate with one another) such as serotonin. Drugs that block certain types of serotonin receptors have been shown to improve cognition in studies, but no medications are currently FDA-approved with this mechanism of action. Biotie ...
Researchers: Christopher Kenney, MD
Research Grant, 2014
The dopamine precursor levodopa is the gold-standard treatment for Parkinson's disease. However, as PD progresses, serotonin neurons increasingly convert levodopa to dopamine as a "false neurotransmitter." This activity underlies the development of troubling levodopa-induced dyskinesia that affects many PD patients. One strategy is to silence the activity of sero...
Rapid Response Innovation Awards, 2014
Aggregation of the protein alpha-synuclein is toxic to dopamine neurons. Therefore, a compound that reduces or clears this protein could be a viable therapeutic option. We have compelling evidence that chemical compounds called tricyclics (primarily used as antidepressants) significantly reduce alpha-synuclein aggregation in a new Parkinson's disease model. This pr...
Research Grant, 2013
Promising Outcomes of Original Grant:
Researchers investigated the effects of serotonin 5-HT1A biased agonists on rotation behavior in pre-clinical models. The scientists used a pre-synaptic (before impulse is conveyed) 5-HT1A preferential agonist. It stimulated rotation behavior by itself and, at a low dose, this effect was increased by co-administration with levodopa. The effects of the drug were...
Researchers: Adrian Newman-Tancredi, PhD, DSc
Rapid Response Innovation Awards, 2012
Levodopa continues to be the gold-standard therapy for patients with Parkinson's disease (PD). Unfortunately, effective long-term treatment is beset by abnormal involuntary movements, also known as dyskinesias. Research evidence indicates that aberrant neuroplasticity in serotonin neurons contributes significantly to the expression of dyskinesias. Studies in this ...